Revolutionizing Medicinal Chemistry: The Application of Artificial Intelligence (AI) in Early Drug Discovery
Artificial intelligence (AI) has permeated various sectors, including the pharmaceutical industry and research, where it has been utilized to efficiently identify new chemical entities with desirable properties. The application of AI algorithms to drug discovery presents both remarkable opportunities and challenges. This review article focuses on the transformative role of AI in medicinal chemistry. We delve into the applications of machine learning and deep learning techniques in drug screening and design, discussing their potential to expedite the early drug discovery process. In particular, we provide a comprehensive overview of the use of AI algorithms in predicting protein structures, drug–target interactions, and molecular properties such as drug toxicity. While AI has accelerated the drug discovery process, data quality issues and technological constraints remain challenges. Nonetheless, new relationships and methods have been unveiled, demonstrating AI’s expanding potential in predicting and understanding drug interactions and properties. For its full potential to be realized, interdisciplinary collaboration is essential. This review underscores AI’s growing influence on the future trajectory of medicinal chemistry and stresses the importance of ongoing synergies between computational and domain experts.
Top-30
Journals
1
2
|
|
Pharmaceuticals
2 publications, 6.45%
|
|
ACS Infectious Diseases
2 publications, 6.45%
|
|
Intelligent Pharmacy
2 publications, 6.45%
|
|
Journal of Molecular Structure
2 publications, 6.45%
|
|
Briefings in Bioinformatics
1 publication, 3.23%
|
|
Receptors
1 publication, 3.23%
|
|
Talanta
1 publication, 3.23%
|
|
Russian Chemical Reviews
1 publication, 3.23%
|
|
Future Journal of Pharmaceutical Sciences
1 publication, 3.23%
|
|
Drug Discovery Today
1 publication, 3.23%
|
|
Biocatalysis and Agricultural Biotechnology
1 publication, 3.23%
|
|
Nano TransMed
1 publication, 3.23%
|
|
Molecules
1 publication, 3.23%
|
|
Methods in Microbiology
1 publication, 3.23%
|
|
AAPS PharmSciTech
1 publication, 3.23%
|
|
Journal of Drug Targeting
1 publication, 3.23%
|
|
Expert Review of Precision Medicine and Drug Development
1 publication, 3.23%
|
|
Ageing Research Reviews
1 publication, 3.23%
|
|
International Journal of Pharmaceutics
1 publication, 3.23%
|
|
Current Opinion in Structural Biology
1 publication, 3.23%
|
|
Journal of Chemical Information and Modeling
1 publication, 3.23%
|
|
Marketing the Green School
1 publication, 3.23%
|
|
ACS Chemical Neuroscience
1 publication, 3.23%
|
|
European Journal of Pharmacology
1 publication, 3.23%
|
|
PLoS ONE
1 publication, 3.23%
|
|
1
2
|
Publishers
2
4
6
8
10
12
14
|
|
Elsevier
14 publications, 45.16%
|
|
MDPI
4 publications, 12.9%
|
|
American Chemical Society (ACS)
4 publications, 12.9%
|
|
Springer Nature
2 publications, 6.45%
|
|
Taylor & Francis
2 publications, 6.45%
|
|
Oxford University Press
1 publication, 3.23%
|
|
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 3.23%
|
|
Research Square Platform LLC
1 publication, 3.23%
|
|
IGI Global
1 publication, 3.23%
|
|
Public Library of Science (PLoS)
1 publication, 3.23%
|
|
2
4
6
8
10
12
14
|
- We do not take into account publications without a DOI.
- Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
- Statistics recalculated weekly.